TITLE

AZATHIOPRINE REDUCES RELAPSE RATE IN CROHN'S DISEASE PATIENTS IN STEROID INDUCED CLINICAL REMISSION BUT WITH ELEVATED FAECAL CALPROTECTIN

PUB. DATE
April 2004
SOURCE
Gut;Apr2004 Supplement 3, Vol. 53, pA101
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Several surrogate markers of mucosal inflammation have been shown by researchers and others to be useful in predicting relapse after remission induced by corticosteroids in Crohn's disease. High risk of relapse in those with elevated faecal calprotectin after medical induction of remission in Crohn's disease may be significantly attenuated by treatment with azathioprine over one year period compared with mesalazine alone. This study provides support for the use of faecal calprotectin as a therapeutic endpoint.
ACCESSION #
13219210

 

Related Articles

  • Beyond these insights there are further applications and future challenges. Jolobe, O. // QJM: An International Journal of Medicine;Apr2010, Vol. 103 Issue 4, p277 

    The article focuses on the study about the genetic susceptibility to Crohn's disease (CD). It states that the genetic susceptibility to CD would be incomplete without recognition that the unrivalled success of azathioprine in inducing and maintaining remission in corticosteroid-dependent CD. It...

  • Cost of Illness of Crohn's Disease. Bodger, K. // PharmacoEconomics;2002, Vol. 20, p639 

    Crohn's disease is a chronic inflammatory bowel disease of unknown aetiology which affects around 35 000 people in the UK (population 56.8 million). The potential for onset in early adult life, disease chronicity and a need for hospitalisation and surgery mean that the disease can be associated...

  • Budesonide capsules cause fewer glucocorticoid-related adverse effects than prednisolone during short-term therapy for active Crohn's disease in adults.  // Drugs & Therapy Perspectives;Jun2003, Vol. 19 Issue 6, p1 

    Budesonide is a corticosteroid with a high degree of topical activity and, when taken orally, has low systemic bioavailability (11%). The capsule formulation of budesonide (Entocort® EC capsules) dissolves in a pH-dependent manner, thereby delaying dissolution until the drug reaches the...

  • Novel treatment for Crohn's found to be more effective. Tanday, Sanjay // GP: General Practitioner;2/29/2008, p6 

    The article reports that a safe and effective ways of treating Crohn's disease has been developed which could eradicate the need for harmful steroids. Presently, corticosteroids is used to treat Crohn's disease to control the patients symptoms before immune-suppressing drugs to prepare the body...

  • Corticosteroids in Crohn’s disease. Yang, Yu-Xiao; Lichtenstein, Gary R. // American Journal of Gastroenterology;Apr2002, Vol. 97 Issue 4, p803 

    Crohn’s disease is a lifelong illness characterized by chronic recurrent flares. The precise etiology of Crohn’s disease is unknown. However, it appears to involve an enhanced systemic immune response and intensified local intestinal mucosal inflammatory activity, mediated through...

  • Bone mineral density in Crohn’s disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Cino, Maria; Greenberg, Gordon R. // American Journal of Gastroenterology;Apr2002, Vol. 97 Issue 4, p915 

    OBJECTIVE:Corticosteroids may contribute to the bone loss associated with Crohn’s disease (CD). We investigated the effect on bone mineral density (BMD) of treatment with budesonide, a steroid with low systemic activity, and compared the outcome with prednisone and nonsteroid therapy in...

  • Progress in Treatment for Crohn's Disease. Brzezinski, Aaron // American Journal of Gastroenterology;Mar2001, Vol. 96 Issue 3, p626 

    Talks about the developments in the treatment of Crohn's disease. Effectiveness of sulfasalazine; Side effects of corticosteroids; Other pharmacological agents used in the treatment of Crohn's disease.

  • Alternate-Day Prednisone Treatment and Treatment Maintenance in Crohn's Disease. Bello, Cesar; Goldstein, Franz; Thornton, James J. // American Journal of Gastroenterology;Apr1991, Vol. 86 Issue 4, p460 

    We have reviewed our data from 55 patients with Crohn's disease (CD) treated with alternate-day prednisone (average dose: 25 mg every other morning) between 1966 and 1989 for a mean duration of 6.6 yr. Daily divided corticosteroid doses were given to all patients with active disease that had not...

  • A BALANCING VIEW: Lifetime Channeling of Infliximab for Crohn's Disease. Hanauer, Stephen B. // American Journal of Gastroenterology;Jul2005, Vol. 100 Issue 7, p1438 

    The article discusses the channeling of infliximab for Crohn's disease. Infliximab is currently indicated for reducing signs and symptoms and inducing and maintaining clinical remission in patients with moderately to severely active Crohn's disease who have had an inadequate response to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics